Pharmacotherapy of adolescent depression - fluoxetine monotherapy or combined treatment?

[1] American psychiatric association. Diagnostic and statistical manual of mental disorders. DSM-5. 5th ed. Arlington, VA: American Psychiatric Association; 2013. ISBN 978-0-89042-554-1.Search in Google Scholar

[2] Corya SA, Williamson D, Sanger TM, Briggs SD, et al. (2006). A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 23:364–372.Search in Google Scholar

[3] DeFilippis M, Wagner KD. Management of treatment-resistant depression in children and adolescents. Paediatr Drugs. 2014 Oct;16(5):353-61.10.1007/s40272-014-0088-y25200567Search in Google Scholar

[4] Detke HC, Delbello MP, Landry J, Usher RW. Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2015;54(3):217–224.10.1016/j.jaac.2014.12.01225721187Search in Google Scholar

[5] Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41 (10): 1205-1215.10.1097/00004583-200210000-0001012364842Search in Google Scholar

[6] Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54 (11): 1031-1037.10.1001/archpsyc.1997.018302300690109366660Search in Google Scholar

[7] Farsky I, Smetanka A, Dubinska S. Spiritualita pacientov s vybranymi psychiatrickymi diagnozami. Osetrovatelstvi a porodni asistence. 2012;3(3):433–441.Search in Google Scholar

[8] Food and drug administration (FDA). Antidepressant Medications: Use in Pediatric Patients. 2015. In https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/ad-pediatric-factsheet11-14.pdfSearch in Google Scholar

[9] Heiligenstein JH, Hoog SL, Wagner KD, Findling RL, et al. Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study. J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):207-17.10.1089/cap.2006.16.20716553541Search in Google Scholar

[10] Kennard B, Silva S, Vitiello B, Curry J, et al. TADS Team. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1404-11.10.1097/01.chi.0000242228.75516.2117135985Search in Google Scholar

[11] March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292 (7): 807-820.10.1001/jama.292.7.80715315995Search in Google Scholar

[12] Mayes TL, Tao R, Rintelmann JW, Carmody T, et al. Do children and adolescents have differential response rates in placebo-controlled trials of fluoxetine? CNS Spectr. 2007 Feb;12(2):147-54.10.1017/S1092852900020666Search in Google Scholar

[13] Ondrejka I. Liečba psychofarmakami vdetskom aadolescentnom veku. In: Psychofarmakológia. Vyd. Wolters Kluwer, 2016. S. 467-502. ISBN: 978-80-8168-543-9.Search in Google Scholar